Litigation Details for HUMANA INC. v. INDIVIOR INC. (E.D. Pa. 2020)

HUMANA INC. v. INDIVIOR INC. (E.D. Pa. 2020)

Docket		Date Filed	2020-09-18
Court	District Court, E.D. Pennsylvania	Date Terminated	2021-07-22
Cause	18:1962 Racketeering (RICO) Act	Assigned To	Mitchell S. Goldberg
Jury Demand	Plaintiff	Referred To
Patents	8,475,832; 8,921,387; 8,975,270; 9,180,197; 9,186,413; 9,272,044
Link to Docket	External link to docket

Details for HUMANA INC. v. INDIVIOR INC. (E.D. Pa. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-18				External link to document
2020-09-18	1	Complaint (Attorney)	Patent Title Number (1) 8,475,832 Sublingual and buccal…Title Number (I) 8,475,832 Sublingual and buccal film compositions …MonoSol patent asserted there, MonoSol and Indivior obtained new patents, and asserted a new patent (in …e. Patents: Patent Patent Title …Page 11 of 211 prosecuted patents on Suboxone in the United States Patent Office; it secured at least	External link to document

Humana Inc. v. Indivior Inc. Litigation Summary and Antitrust Analysis, 2:20-cv-04602

Last updated: August 18, 2026

Humana Inc. v. Indivior Inc., No. 2:20-cv-04602, is a Suboxone antitrust action brought by a health insurer against Indivior. The case concerns alleged conduct intended to delay generic competition to Suboxone, a buprenorphine-naloxone product used to treat opioid-use disorder. The dispute is part of the broader multidistrict litigation consolidated in the Eastern District of Pennsylvania as In re Suboxone Antitrust Litigation, MDL No. 2445.

The principal theories involve product switching from Suboxone tablets to Suboxone film, alleged manipulation of the FDA regulatory process, and conduct that allegedly delayed or impeded generic film competition. The case is not a conventional patent-infringement action. Its commercial significance arises from alleged antitrust injury, including higher reimbursement costs incurred by payers such as Humana.

What is Humana Inc. v. Indivior Inc.?

Humana filed the action in the U.S. District Court for the Eastern District of Pennsylvania under civil action number 2:20-cv-04602. The defendant is Indivior Inc., the U.S. operating company associated with Suboxone.

The case concerns alleged overcharges for Suboxone and related products. Humana’s position is based on the premise that generic competition would have entered earlier, or expanded more rapidly, absent Indivior’s allegedly anticompetitive conduct.

Core allegations

The allegations track the theories litigated in the Suboxone MDL:

1. Indivior allegedly shifted the market from Suboxone tablets to Suboxone sublingual film before generic tablet competition became effective.
2. Indivior allegedly withdrew or reduced support for the tablet product to encourage patients, physicians and pharmacies to move to film.
3. Indivior allegedly made representations to the FDA concerning the risks associated with generic film products.
4. Indivior allegedly used regulatory and commercial strategies to delay generic entry.
5. Health plans and other payers allegedly paid more for Suboxone than they would have paid in a competitive market.

These theories are commonly described as “product hopping” and “regulatory manipulation.” The relevant legal claims are antitrust claims rather than claims that Humana infringed or invalidated an Indivior patent.

What court handled the Humana v. Indivior case?

The case was filed in the Eastern District of Pennsylvania and became part of the Suboxone multidistrict litigation before Judge Mitchell S. Goldberg.

The MDL consolidated actions involving alleged exclusionary conduct relating to Suboxone tablets and film. Consolidation permitted common treatment of discovery, motions, expert issues and class-related questions while preserving the individual claims of participating plaintiffs.

Item	Detail
Case	Humana Inc. v. Indivior Inc.
Civil action number	2:20-cv-04602
Court	U.S. District Court for the Eastern District of Pennsylvania
Subject	Suboxone antitrust claims
MDL	In re Suboxone Antitrust Litigation, MDL No. 2445
Defendant	Indivior Inc.
Plaintiff	Humana Inc.
Product	Suboxone, buprenorphine hydrochloride and naloxone hydrochloride
Case type	Commercial antitrust litigation
Patent-infringement claims	Not the principal claims in the action

The MDL structure matters because rulings in the consolidated proceeding could affect Humana’s proof of liability, market definition, causation, damages and class-related issues.

What conduct did Humana challenge?

Humana challenged Indivior’s alleged strategy to replace Suboxone tablets with film before generic competition could materially reduce prices.

Product switching from tablets to film

Suboxone was marketed in both tablet and sublingual-film forms. Generic tablet competition entered the market before equivalent generic film competition became available. The alleged product-hopping theory is that Indivior promoted film and reduced the commercial viability of tablets, limiting the ability of generic tablet manufacturers to constrain prices.

The legal issue is not whether a company may introduce an improved product. A product change can be lawful when it reflects genuine innovation and consumers can choose between products. The antitrust question is whether the defendant used market power to make the older product unavailable or commercially unattractive for the purpose of preventing substitution to lower-priced generic products.

FDA citizen-petition allegations

The broader Suboxone litigation also examined Indivior’s FDA communications regarding generic film products. Plaintiffs alleged that Indivior raised safety concerns about generic film products in a manner designed to delay FDA approval or commercial uptake.

FDA petitions are protected in many circumstances under the Noerr-Pennington doctrine. That protection can be limited where a petition is objectively baseless and intended to interfere directly with a competitor through governmental process. The Third Circuit’s treatment of the Suboxone claims allowed the litigation to proceed past an early pleading challenge and recognized that the alleged regulatory conduct had to be evaluated in the full factual and competitive context. [1]

What were the principal legal theories?

Humana’s case is best understood as a Sherman Act Section 2 exclusionary-conduct case, supported by related theories concerning monopolization, attempted monopolization and restraint of trade.

Monopolization and exclusionary conduct

The alleged market was narrower than the entire opioid-use-disorder market. Plaintiffs focused on products containing buprenorphine and naloxone, particularly sublingual formulations used as alternatives to Suboxone.

A monopolization claim generally requires proof of:

• A relevant product and geographic market.
• Monopoly power or the ability to control prices or exclude competition.
• Exclusionary conduct rather than competition on the merits.
• Antitrust injury and damages.

Humana’s economic theory depends on showing that generic entry would have produced lower prices and that Indivior’s conduct caused the delay or reduced the impact of that competition.

Antitrust injury

Humana would need to connect the alleged conduct to payments it made for Suboxone or related products. The relevant damages model would generally compare actual payments with a but-for scenario in which generic competition entered or expanded without the alleged exclusionary conduct.

The key causation issues include:

• Whether generic tablet entry would have produced meaningful substitution.
• Whether patients and prescribers would have accepted tablets instead of film.
• Whether generic film products would have entered earlier absent Indivior’s conduct.
• Whether reimbursement policies, rebates and formulary placement reduced or increased the alleged overcharge.
• Whether Humana purchased directly or indirectly through intermediaries and how that affects damages proof.

What did the Third Circuit decide in the Suboxone litigation?

The Third Circuit allowed significant Suboxone antitrust claims to proceed beyond the pleading stage in In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, 967 F.3d 264 (3d Cir. 2020).

The appellate ruling addressed whether the plaintiffs had adequately alleged antitrust injury and exclusionary conduct. The decision was important to Humana and other payers because it rejected an early dismissal framework that would have prevented plaintiffs from developing a factual record concerning product switching, generic entry and regulatory conduct.

The decision did not establish final liability. It preserved factual questions concerning:

• The relevant market.
• Indivior’s market power.
• The purpose and effect of the tablet-to-film transition.
• The competitive significance of the alleged FDA conduct.
• The timing and effect of generic entry.
• The amount of damages.

What is the status of Humana’s individual case?

Humana’s action was placed within the Suboxone MDL. Publicly reported proceedings in the MDL, rather than the standalone case caption alone, provide the principal procedural context for the litigation.

The action should therefore be analyzed in three layers:

1. The individual Humana complaint and its damages claim.
2. The common MDL rulings governing liability and economic proof.
3. Any settlement, dismissal, release or administrative closure affecting Humana specifically.

The available case identification establishes the filing and MDL context, but a standalone case number does not by itself establish a final judgment on the merits. The key business question is whether Humana’s claims were resolved through an MDL settlement, dismissed, released or continued under coordinated proceedings.

Was Humana involved in a Paragraph IV patent challenge?

No Paragraph IV challenge is identified as the principal subject of Humana’s action.

A Paragraph IV certification is filed by an abbreviated new drug application applicant asserting that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. That process is typically pursued by a generic manufacturer, not by a health insurer.

Humana’s case instead concerns the commercial consequences of alleged delayed generic competition. Any Suboxone patent litigation and FDA approval activity is relevant as background to the antitrust damages analysis, but the Humana action does not appear to be a patent-validity case.

What patents protected Suboxone?

Suboxone was protected by a combination of patents, regulatory exclusivities, trademarks, product formulations and commercial know-how. The important patent question for the antitrust case is not simply when an individual patent expired. It is whether generic manufacturers could have entered and competed effectively despite the remaining patent, regulatory and commercial barriers.

Patent issues relevant to the case

The litigation may involve evidence concerning:

• Patents covering buprenorphine-naloxone compositions.
• Patents covering sublingual film formulations.
• Patents covering film manufacturing and dosage delivery.
• Orange Book-listed patents associated with approved Suboxone products.
• Patent settlements between Indivior and generic manufacturers.
• FDA approval dates for generic tablet and film products.

Patent protection can lawfully delay generic entry. The antitrust analysis turns on whether Indivior exceeded lawful patent enforcement or product development and used deception, sham regulatory conduct or exclusionary product changes to extend market power beyond the legitimate scope of its intellectual-property rights.

What was the FDA and Orange Book significance?

Suboxone’s FDA history is central to the competitive narrative.

Suboxone film was approved as a treatment for opioid dependence and later opioid-use disorder. Generic competition developed through separate approval pathways for tablet and film products. The distinction matters because generic tablet competition did not necessarily provide the same competitive constraint as generic film competition.

The Orange Book can identify patents and exclusivity information associated with approved products. It does not determine whether broader conduct was anticompetitive. An Orange Book listing can support lawful patent enforcement, but a listing does not immunize independent conduct that allegedly prevents substitution or misleads regulators.

The principal regulatory questions are:

• When did the FDA approve generic buprenorphine-naloxone tablets?
• When did the FDA approve generic film products?
• Did FDA safety communications delay approval or market uptake?
• Did Indivior’s citizen petitions affect the timing of generic entry?
• Did the tablet-to-film transition reduce the practical value of generic tablet approval?

How strong was Humana’s antitrust case?

Humana’s case had material pleading strength because the theory was supported by a broader factual record involving product conversion, generic entry timing and alleged regulatory conduct. The Third Circuit’s 2020 decision allowed the central Suboxone theories to proceed, reducing the risk of early dismissal.

The principal strengths were:

• A coherent theory linking product conversion to generic-entry delay.
• A payer plaintiff with a direct economic interest in drug spending.
• A market structure in which small timing differences could create substantial damages.
• Prior regulatory and commercial events that could be tested through documents and expert analysis.
• Appellate precedent permitting factual development.

The principal weaknesses were:

• The need to distinguish lawful product improvement from exclusionary product hopping.
• The difficulty of proving that generic tablets would have substantially displaced film.
• The need to isolate the effect of rebates, formularies and prescribing behavior.
• Causation issues tied to FDA review and generic manufacturers’ independent decisions.
• Potential defenses based on patent rights, FDA regulation and legitimate product safety concerns.
• Complex pass-through and reimbursement issues affecting Humana’s damages.

What damages exposure did Indivior face?

The potential exposure arose from alleged overpayments for Suboxone and related products. Damages could include the difference between actual prices and estimated competitive prices during the alleged exclusion period, subject to proof of causation and applicable antitrust limitations.

Potential exposure depended on:

• Humana’s covered lives and utilization.
• The period during which generic competition was allegedly suppressed.
• The price difference between branded Suboxone and generic alternatives.
• The share of patients who could have switched to tablets or generic film.
• Rebates and other concessions paid by Indivior.
• The geographic and product scope of the relevant market.
• Whether damages were trebled under federal antitrust law.

The existence of a large aggregate MDL does not establish the amount recoverable by Humana. Individual payer damages require separate transactional and utilization evidence.

Did Indivior enter settlements in the Suboxone litigation?

Indivior has faced substantial civil, regulatory and criminal exposure relating to Suboxone marketing and competition issues. The U.S. Department of Justice announced a 2020 resolution involving Indivior that included criminal and civil components and addressed allegations concerning opioid-treatment products. [2]

Separate private antitrust settlements in the broader Suboxone litigation have involved class and other plaintiffs. A settlement affecting one plaintiff group does not automatically resolve every individual action. The release language, plaintiff participation, opt-out status and case-specific dismissal documents determine whether Humana’s claims were extinguished or remained active.

For transaction and litigation-risk purposes, the relevant documents are:

• The applicable MDL settlement agreement.
• Any class-notice and release provisions.
• Humana’s election or exclusion status.
• Stipulations of dismissal.
• Orders administratively closing or remanding the case.
• Any confidential or case-specific resolution.

What generic-entry risks existed for Suboxone?

The case illustrates several generic-entry risks that apply to branded combination products:

Formulation substitution risk

Generic tablets may not impose the same price pressure as generic film if patients, prescribers or payers prefer film. A brand can reduce tablet substitution by moving demand to the protected or less-contested formulation.

Manufacturing barriers

Sublingual films require specialized manufacturing controls, dosage uniformity, packaging and quality systems. These requirements can make film entry more difficult than tablet entry even after basic patent barriers are addressed.

Regulatory barriers

FDA review, citizen petitions, product-specific safety issues and approval timing can affect the commercial launch date of a generic. The delay between approval and actual market entry can materially change damages.

Commercial barriers

Formulary placement, rebates, physician preferences, patient familiarity and pharmacy substitution rules can limit the impact of a nominally available generic.

How does the case compare with a conventional pharmaceutical patent dispute?

Issue	Humana v. Indivior	Conventional patent case
Plaintiff	Health insurer	Patent holder or alleged infringer
Core claim	Antitrust overcharges	Patent infringement or invalidity
Main evidence	Market conduct, pricing, entry and substitution	Claims, specifications, prosecution history and infringement
Remedy	Damages, potentially trebled	Injunction, damages or declaration
FDA role	Evidence of entry timing and regulatory conduct	ANDA approval and patent certification
Paragraph IV issue	Background only	Often central
Patent validity	Not the primary issue	Usually central
Economic question	But-for generic competition and overcharge	Reasonable royalty or lost profits

The case is therefore more relevant to commercial-exclusivity risk than to claim-construction risk. A company can prevail on patent enforcement while still facing antitrust scrutiny for separate conduct designed to prevent substitution.

What is the commercial significance for Humana and Indivior?

For Humana, the case represents a potential recovery opportunity tied to historic prescription-drug spending. It also provides a vehicle to challenge conduct that may have raised costs for commercial and government-sponsored health plans.

For Indivior, the case creates exposure beyond ordinary patent expiration. The company’s risk includes damages, litigation costs, discovery of product and regulatory strategy, and possible effects on future product-switching strategies.

For generic manufacturers, the litigation record provides a framework for evaluating:

• Film-manufacturing investments.
• Patent settlement timing.
• FDA petition risk.
• Market conversion before generic launch.
• The effect of branded formulation changes on substitution.

Key Takeaways

• Humana Inc. v. Indivior Inc., No. 2:20-cv-04602, is a Suboxone antitrust case, not a conventional patent-infringement action.
• The claims focus on alleged product switching from Suboxone tablets to film and alleged efforts to delay or weaken generic competition.
• The case was part of the Eastern District of Pennsylvania Suboxone MDL, MDL No. 2445.
• The Third Circuit’s 2020 decision allowed central Suboxone antitrust theories to proceed beyond the pleading stage.
• Humana’s damages theory depends on proving that generic competition would have entered earlier or had a greater commercial effect.
• Paragraph IV patent challenges are relevant background but are not the principal claims asserted by Humana.
• Patent rights, FDA review, manufacturing complexity and formulary behavior all affect the generic-entry analysis.
• Any final resolution of Humana’s claims must be determined from the applicable MDL settlement, dismissal or case-disposition documents.

Frequently Asked Questions

What drug was at issue in Humana v. Indivior?

The case concerns Suboxone, a buprenorphine-naloxone product marketed for opioid-use disorder. The dispute involves tablet and sublingual-film formulations.

Was Humana suing Indivior for patent infringement?

No. Humana’s action is an antitrust and overcharge case. Patent rights and generic certifications are relevant to the background, but the case does not principally seek a ruling that an Indivior patent is invalid or infringed.

Does the case affect generic buprenorphine-naloxone manufacturers?

Yes. The litigation concerns the commercial and regulatory conditions under which generic buprenorphine-naloxone products entered the market. Its findings can affect how generic manufacturers assess product-switching and regulatory-delay theories.

Can a brand legally switch patients from tablets to film?

Yes, if the conduct reflects legitimate competition and does not unlawfully prevent customers from choosing competing products. The antitrust issue is whether the switch was used to block generic substitution rather than to compete on product merits.

Does an Orange Book patent automatically justify delayed generic entry?

No. An Orange Book patent can create lawful patent-related barriers, but it does not immunize separate conduct that allegedly involves sham regulatory activity, deception or exclusionary product switching.

References

[1] U.S. Court of Appeals for the Third Circuit. (2020). In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, 967 F.3d 264.

[2] U.S. Department of Justice. (2020, November 24). Indivior agrees to pay $600 million to resolve criminal and civil liability arising from opioid marketing and sales practices. https://www.justice.gov/

[3] U.S. District Court for the Eastern District of Pennsylvania. (2020). Humana Inc. v. Indivior Inc., No. 2:20-cv-04602.

[4] U.S. District Court for the Eastern District of Pennsylvania. (2013). In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, MDL No. 2445.

[5] U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm